CGON Stock Price, Chart, Stats & News

CG Oncology, Inc. Common stock
Save
5.84B
Market cap
–
Current P/E
–
Forward P/E
CGON chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -15.02% |
Operating margin | -4722.13% |
Pretax margin | -3985.02% |
Net margin | -3985.02% |
Effective tax rate | – |
ROA | -20.34% |
ROE | -22.87% |
D/E | 0.01x |
Interest coverage ratio | – |
CGON valuation
P/E | – |
P/S | 1350.55x |
P/B | 6.64x |
P/CF | -37.74x |
P/FCF | -41.19x |
P/OCF | -37.74x |
PEG | 21.20x |
EV multiple | -32.77x |
About
CG Oncology Inc. is a biotechnology company in the clinical development stage, committed to advancing and bringing to market an innovative, bladder-sparing core treatment for individuals diagnosed with bladder cancer. Their principal drug candidate, cretostimogene, is presently undergoing clinical evaluation. Its initial focus is on providing a therapeutic option for patients suffering from high-risk Non-Muscle Invasive Bladder Cancer who have not responded to Bacillus Calmette Guerin (BCG) therapy, which represents the established standard of care for this particular severe form of NMIBC.
Similar securities
Based on sector and market capitalization
Report issue











